These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 28694704)

  • 1. Health care provider experience with canagliflozin in real-world clinical practice: favorability, treatment patterns, and patient outcomes.
    Bolge SC; Flores NM; Huang S; Cai J
    Int J Gen Med; 2017; 10():177-187. PubMed ID: 28694704
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quality measure and weight loss assessment in patients with type 2 diabetes mellitus treated with canagliflozin or dipeptidyl peptidase-4 inhibitors.
    Wysham CH; Lefebvre P; Pilon D; Ingham M; Lafeuille MH; Emond B; Kamstra R; Chow W; Pfeifer M; Duh MS
    BMC Endocr Disord; 2017 Jun; 17(1):32. PubMed ID: 28595617
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CANadian CAnagliflozin REgistry: Patient-Reported Outcomes of Canagliflozin in the Treatment of Type 2 Diabetes Mellitus in Canadian Clinical Practice.
    Woo V; Bell A; Clement M; Noronha L; Tsoukas MA; Camacho F; Traina S; Georgijev N; Rose JB; Sorabji D; Bajaj HS
    Can J Diabetes; 2019 Oct; 43(7):464-471. PubMed ID: 31133438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of Canagliflozin Treatment on Health-Related Quality of Life among People with Type 2 Diabetes Mellitus: A Pooled Analysis of Patient-Reported Outcomes from Randomized Controlled Trials.
    Cai J; Delahanty LM; Akapame S; Slee A; Traina S
    Patient; 2018 Jun; 11(3):341-352. PubMed ID: 29313267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Second-line Glucose-Lowering Therapy in Type 2 Diabetes Mellitus.
    Shin JI
    Curr Diab Rep; 2019 Jul; 19(8):54. PubMed ID: 31286271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The association of weight loss with patient experience and outcomes in a population of patients with type 2 diabetes mellitus prescribed canagliflozin.
    Gerlanc NM; Cai J; Tkacz J; Bolge SC; Brady BL
    Diabetes Metab Syndr Obes; 2017; 10():89-99. PubMed ID: 28360528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short-term outcomes of patients with Type 2 diabetes mellitus treated with canagliflozin compared with sitagliptin in a real-world setting.
    Shao YL; Yee KH; Koh SK; Wong YF; Yeoh LY; Low S; Sum CF
    Singapore Med J; 2018 May; 59(5):251-256. PubMed ID: 29022040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-Effectiveness of Canagliflozin versus Sitagliptin as Add-on to Metformin in Patients with Type 2 Diabetes Mellitus in Mexico.
    Neslusan C; Teschemaker A; Johansen P; Willis M; Valencia-Mendoza A; Puig A
    Value Health Reg Issues; 2015 Dec; 8():8-19. PubMed ID: 29698175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of Canagliflozin in Combination With and Compared to Incretin-Based Therapies in Type 2 Diabetes.
    Pratley RE; Cersosimo E
    Clin Diabetes; 2017 Jul; 35(3):141-153. PubMed ID: 28761216
    [No Abstract]   [Full Text] [Related]  

  • 10. Promoting and supporting self-management for adults living in the community with physical chronic illness: A systematic review of the effectiveness and meaningfulness of the patient-practitioner encounter.
    Rees S; Williams A
    JBI Libr Syst Rev; 2009; 7(13):492-582. PubMed ID: 27819974
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-Effectiveness Analysis of Canagliflozin 300 mg Versus Dapagliflozin 10 mg Added to Metformin in Patients with Type 2 Diabetes in the United States.
    Neslusan C; Teschemaker A; Willis M; Johansen P; Vo L
    Diabetes Ther; 2018 Apr; 9(2):565-581. PubMed ID: 29411292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Update on SGLT2 Inhibitors-New Data Released at the American Diabetes Association.
    Lee S
    Crit Pathw Cardiol; 2017 Sep; 16(3):93-95. PubMed ID: 28742644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SGLT2 inhibitors as add on therapy in type 2 diabetes: a real world study.
    Tamez-Perez HE; Delgadillo-Esteban E; Soni-Duque D; Hernández-Coria MI; Tamez-Peña AL
    J Diabetes Metab Disord; 2017; 16():27. PubMed ID: 28680862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Health care provider management of patients with type 2 diabetes mellitus: analysis of trends in attitudes and practices.
    Williamson C; Glauser TA; Burton BS; Schneider D; Dubois AM; Patel D
    Postgrad Med; 2014 May; 126(3):145-60. PubMed ID: 24918800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study.
    Patorno E; Goldfine AB; Schneeweiss S; Everett BM; Glynn RJ; Liu J; Kim SC
    BMJ; 2018 Feb; 360():k119. PubMed ID: 29437648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial.
    Bode B; Stenlöf K; Sullivan D; Fung A; Usiskin K
    Hosp Pract (1995); 2013 Apr; 41(2):72-84. PubMed ID: 23680739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quality of Prescribing by Physicians, Nurse Practitioners, and Physician Assistants in the United States.
    Jiao S; Murimi IB; Stafford RS; Mojtabai R; Alexander GC
    Pharmacotherapy; 2018 Apr; 38(4):417-427. PubMed ID: 29457258
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simultaneous Reduction in Both HbA1c and Body Weight with Canagliflozin Versus Glimepiride in Patients with Type 2 Diabetes on Metformin.
    Leiter LA; Langslet G; Vijapurkar U; Davies MJ; Canovatchel W
    Diabetes Ther; 2016 Jun; 7(2):269-78. PubMed ID: 26984361
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of Canagliflozin Used in Conjunction with Sulfonylurea in Patients with Type 2 Diabetes Mellitus: A Randomized, Controlled Trial.
    Fulcher G; Matthews DR; Perkovic V; de Zeeuw D; Mahaffey KW; Weiss R; Rosenstock J; Capuano G; Desai M; Shaw W; Vercruysse F; Meininger G; Neal B
    Diabetes Ther; 2015 Sep; 6(3):289-302. PubMed ID: 26081793
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.